Abstract: A pharmaceutical formulation, comprising a phosphatidylcholine product of formula (I), wherein R1 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and R2 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and wherein the phosphatidylcholine product (PC) contains the following amounts of fatty acids: 55-72 linoleic acid; 10 18 palmitic acid; 07 15 oleic acid; 02 08 linolenic acid; 02 08 stearic acid, and at least one excipient for delayed release, can be used for the improved treatment of ulcerative colitis.

Abstract: Disclosed herein are compounds pharmaceutical compositions containing same of the formula1. A compound of the Formula ##STR1## wherein X, X', X" and X'", A, B, D, R, and R' are as identified in the specification and their preparation. Pharmaceutical compositions containing same can be used in the treatment of cancer.

Abstract: Disclosed herein are compounds pharmaceutical compositions containing same of the formula1. A compound of the Formula ##STR1## wherein X, X', X" and X'", A, B, D, R, and R' are as identified in the specification and their preparation. Pharmaceutical compositions containing same can be used in the treatment of cancer.

Abstract: This invention relates to 1-amino-3-phenoxy-propane-derivatives of formula 1: ##STR1## (in which A, B, R, R.sup.x, X and Z are defined as in the specification described) and methods for their preparation.These compounds may be used as modulators of multidrug resistance in cancer chemotherapy and for circumvention of resistance in the treatment of malaria.

Abstract: Disclosed herein are compounds pharmaceutical compositions containing same of the formula1. A compound of the Formula ##STR1## wherein X, X', X" and X'", A, B, D, R, and R' are as identified in the specification and their preparation. Pharmaceutical compositions containing same can be used in the treatment of cancer.

Abstract: Asymmetrically substituted bisnaphthalimides of the formula I ##STR1## in which A, B, D, R.sup.1, R.sup.2, m and have the meanings stated in the description, and the salts thereof with phsiologically tolerated acids, ale described. The novel compounds are suitable for controlling diseases.

Abstract: An antitumor 5-nitrobenzo[de]isoquinoline-1,3-dione of the formula I ##STR1## where n is 1 or 2, R.sup.1 and R.sup.2 are identical or different and are each hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -hydroxyalkyl, pyrrolidinyl, morpholino, piperidinyl or piperacinyl and R.sup.3 and R.sup.4 are identical or different and are each hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -acyl, C.sub.2 --C.sub.7 -alkoxycarbonyl, ureyl, aminocarbonyl or C.sub.2 -C.sub.7 -alkylaminocarbonyl, and its salts with physiologically tolerated acids, are described.

Abstract: Novel peptides of the formula ##STR1## in which R.sup.1, R.sup.2, X, A, R.sup.3, B, D, E, R.sup.7, M, Q, a, b and d have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.

Abstract: Derivatives of a tumor necrosis factor (TNF), which originate from a modification at the amino terminus of the TNF molecule are suitable for controlling diseases.

Abstract: Polypeptides which differ from lymphotoxin by the absence of amino acids at the N-terminal end of the lymphotoxin are described. The polypeptides can be prepared by gene manipulation and are suitable, alone or in combination with lymphokines, as pharmaceuticals.

Abstract: Novel strobilurine derivatives which are suitable for the treatment of disorders and as fungicides are described.

Abstract: Bisnaphthalimides of the formula I ##STR1## where X.sup.1 to X.sup.4 and R have the meanings stated in the description, and their preparation are described. The compounds are cytotoxic towards human cells in vitro.